These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30769242)

  • 1. Clinical candidates modulating protein-protein interactions: The fragment-based experience.
    Valenti D; Hristeva S; Tzalis D; Ottmann C
    Eur J Med Chem; 2019 Apr; 167():76-95. PubMed ID: 30769242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery.
    Winter A; Higueruelo AP; Marsh M; Sigurdardottir A; Pitt WR; Blundell TL
    Q Rev Biophys; 2012 Nov; 45(4):383-426. PubMed ID: 22971516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces.
    Rooklin D; Wang C; Katigbak J; Arora PS; Zhang Y
    J Chem Inf Model; 2015 Aug; 55(8):1585-99. PubMed ID: 26225450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of in Silico Methods for Design and Development of Drugs Targeting Protein-Protein Interactions.
    Cicaloni V; Trezza A; Pettini F; Spiga O
    Curr Top Med Chem; 2019; 19(7):534-554. PubMed ID: 30836920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulators of 14-3-3 Protein-Protein Interactions.
    Stevers LM; Sijbesma E; Botta M; MacKintosh C; Obsil T; Landrieu I; Cau Y; Wilson AJ; Karawajczyk A; Eickhoff J; Davis J; Hann M; O'Mahony G; Doveston RG; Brunsveld L; Ottmann C
    J Med Chem; 2018 May; 61(9):3755-3778. PubMed ID: 28968506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based drug discovery supports drugging 'undruggable' protein-protein interactions.
    Wang ZZ; Shi XX; Huang GY; Hao GF; Yang GF
    Trends Biochem Sci; 2023 Jun; 48(6):539-552. PubMed ID: 36841635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Motif mediated protein-protein interactions as drug targets.
    Corbi-Verge C; Kim PM
    Cell Commun Signal; 2016 Mar; 14():8. PubMed ID: 26936767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational modulator design by exploitation of protein-protein complex structures.
    Wichapong K; Poelman H; Ercig B; Hrdinova J; Liu X; Lutgens E; Nicolaes GA
    Future Med Chem; 2019 May; 11(9):1015-1033. PubMed ID: 31141413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.
    Scott DE; Bayly AR; Abell C; Skidmore J
    Nat Rev Drug Discov; 2016 Aug; 15(8):533-50. PubMed ID: 27050677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging roles of allosteric modulators in the regulation of protein-protein interactions (PPIs): A new paradigm for PPI drug discovery.
    Ni D; Lu S; Zhang J
    Med Res Rev; 2019 Nov; 39(6):2314-2342. PubMed ID: 30957264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stabilization of Protein-Protein Interactions in chemical biology and drug discovery.
    Bier D; Thiel P; Briels J; Ottmann C
    Prog Biophys Mol Biol; 2015 Oct; 119(1):10-9. PubMed ID: 26093250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fragment-based approaches to the discovery of kinase inhibitors.
    Mortenson PN; Berdini V; O'Reilly M
    Methods Enzymol; 2014; 548():69-92. PubMed ID: 25399642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery?
    Thiel P; Kaiser M; Ottmann C
    Angew Chem Int Ed Engl; 2012 Feb; 51(9):2012-8. PubMed ID: 22308055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.
    Arkin MR; Tang Y; Wells JA
    Chem Biol; 2014 Sep; 21(9):1102-14. PubMed ID: 25237857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the relationship between hub proteins and drug targets based on GO and intrinsic disorder.
    Fu Y; Guo Y; Wang Y; Luo J; Pu X; Li M; Zhang Z
    Comput Biol Chem; 2015 Jun; 56():41-8. PubMed ID: 25854804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using yeast as a model to study membrane proteins.
    Petschnigg J; Moe OW; Stagljar I
    Curr Opin Nephrol Hypertens; 2011 Jul; 20(4):425-32. PubMed ID: 21587075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hotspot Identification and Drug Design of Protein-Protein Interaction Modulators Using the Fragment Molecular Orbital Method.
    Monteleone S; Fedorov DG; Townsend-Nicholson A; Southey M; Bodkin M; Heifetz A
    J Chem Inf Model; 2022 Aug; 62(16):3784-3799. PubMed ID: 35939049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconstructing genome-wide protein-protein interaction networks using multiple strategies with homologous mapping.
    Lo YS; Huang SH; Luo YC; Lin CY; Yang JM
    PLoS One; 2015; 10(1):e0116347. PubMed ID: 25602759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network analysis and in silico prediction of protein-protein interactions with applications in drug discovery.
    Murakami Y; Tripathi LP; Prathipati P; Mizuguchi K
    Curr Opin Struct Biol; 2017 Jun; 44():134-142. PubMed ID: 28364585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterizing Protein-Protein Interactions with the Fragment Molecular Orbital Method.
    Heifetz A; Sladek V; Townsend-Nicholson A; Fedorov DG
    Methods Mol Biol; 2020; 2114():187-205. PubMed ID: 32016895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.